Author: CannabisNewsWire (CNW)

About CannabisNewsWire CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge. To receive SMS text alerts from CannabisNewsWire, text “CANNABIS” to 21000 (U.S. Mobile Phones Only) For more information please visit https://www.CannabisNewsWire.com Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) DehydraTECH Footprint Extends to Europe with License Granted to Valcon Medical

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has awarded licensing of its proprietary DehydraTECH(TM) offering for development in the European and United Kingdom markets. The company awarded the nonexclusive licenses to Valcon Medical A/S, a European contract manufacturing organization that specializes in the manufacturing of medical cannabis extracts for the EU and UK. According to the announcement, Lexaria will receive milestone fees and royalty payments from sales of products manufactured by Valcon.Valcon products will include an array of options, from nonregistered medical products through magistral programs to country-level market-authorized medical cannabis products through pilot programs; they will also include bulk powders or solid oral-dosage forms as well as powder-filled capsules, compressed tablets, pills, oral melts, and topical creams and lotions. “We are very excited to have licensed Lexaria’s DehydraTECH technology for what we expect will be rapid growth across the European markets,” said Valcon Medical A/S CEO Pete Patterson in the press release. “As Valcon continues to build out its manufacturing capabilities, we are developing new IP and partnering with industry leaders. Lexaria has developed and patented an incredible technology, which will benefit medical cannabis patients with enhanced bioavailability with a quicker effect onset. Backed by substantial clinical efficacy studies, Valcon will bridge the extensive work that Lexaria has done in the U.S., over to Europe.”

To view the full press release, visit https://cnw.fm/ffrpT

About Lexaria Bioscience Corp.

Lexaria Bioscience’s patented drug-delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bioabsorption with cannabinoids and nicotine by up to 10 times and, in some instances, with cannabinoids by as much as 27 times compared to standard industry formulations; reduce time of onset from one to two hours to minutes; and mask unwanted tastes; it is also being evaluated for orally administered antiviral drugs, non-steroidal anti-inflammatory drugs (NSAIDs), PDE5 inhibitors and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 25 patents granted and more than 50 patents pending worldwide. For more information about the company, please visit www.LexariaBioscience.com. 

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive SMS text alerts from CannabisNewsWire, text “Cannabis” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces $5M Registered Direct and Private Placement Offerings

InMed Pharmaceuticals (NASDAQ: INM) is a leader in the research, development, manufacturing and commercialization of rare cannabinoids. The company today announced its entry into securities purchase agreements with a single health care-focused institutional investor for the issuance and sale of 4,079,256 of its common shares, each at a purchase price of $0.858 (or pre-funded warrant in lieu thereof), in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, InMed has also agreed to issue and sell to the investor 1,748,250 common shares (or pre-funded warrant in lieu thereto) at the same purchase price as in the registered direct offering. In addition, the company has agreed to issue to the investor in the offerings unregistered preferred investment options to purchase up to an aggregate of 5,827,506 common shares. The company expects aggregate gross proceeds of approximately $5 million through both offerings, which are expected to close on or about June 6, 2022, subject to the satisfaction of customary conditions. InMed intends to use the net proceeds to continue pipeline development, advance commercial activities and for general working capital purposes. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offerings.

To view the full press release, visit https://cnw.fm/VSwXH

About InMed Pharmaceuticals Inc.

InMed Pharmaceuticals is a global leader in the research, development, manufacturing and commercialization of rare cannabinoids. Together with its subsidiary BayMedica LLC, the company has unparalleled cannabinoid manufacturing capabilities to serve a spectrum of consumer markets, including pharmaceutical and health and wellness. InMed is also a clinical-stage company developing a pipeline of rare cannabinoid therapeutics and dedicated to delivering new treatment alternatives to patients who may benefit from cannabinoid-based pharmaceutical drugs. For more information, visit www.InMedPharma.com and www.BayMedica.com.

NOTE TO INVESTORS: The latest news and updates relating to INM are available in the company’s newsroom at https://cnw.fm/INM

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive SMS text alerts from CannabisNewsWire, text “Cannabis” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

420 with CNW — Study Says Cannabis Legalization Has Drastically Changed Marijuana Advertising

A recent study has concluded that the cannabis legalization wave sweeping across states and countries has triggered “drastic changes” in the way marijuana is advertised on Instagram. The research found that women are now more noticeable as “marijuana influencers,” and they drive cannabis marketing by posting about the way marijuana can be incorporated in one’s lifestyle.

This study is in stark contrast to pre-legalization years in which men where the more expected face of advertising illicit marijuana. The profiles of marijuana influencers now are also authentic, while those of the previous lot of marketers were anonymous or almost identifiable as fake because of the prohibition of marijuana in the target markets.

The study, whose findings were published in April, analyzed the profile pages of 60 apparently black-market sellers as well as 70 profile pages of cannabis influencers based within the United  States. The researchers focused a great deal on any notable text or visual differences.

The study findings indicate that Instagram is enabling marijuana influencers to flip the stereotypes about the illicit marijuana sector as being built around men. Today, cannabis is gaining the persona of a female user who wants the substance to meet a certain need in the female lifestyle. Such marketing is making it normal for women to use marijuana in the jurisdictions where it is legal.

The authors of the study note that such changes in the ways through which marijuana is marketed can influence consumption habits as well as shape the debate as people discuss the possibility of legalizing this plant.

The research team was also quick to observe that the current federal prohibition of marijuana had made it harder to market cannabis on social media platforms. This is because those platforms were actively censoring content in a bid to avoid being penalized by the federal government. This censorship takes place even in states where cannabis is legal.

It is now common to find cannabis influencers adding disclaimers to their posts, clarifying that the influencer isn’t in any way attempting to sell marijuana; instead, they note that they are only providing an explanation of the different ways in which they incorporate cannabis products in their lifestyles.

The study also notes that the female-dominated cannabis influencers in the United States largely focus their attention on how marijuana products can be used as lifestyle accessories while the previous generation of marketers tended to focus more on the marijuana itself, rather than its benefits. This shift in marketing now presents cannabis not as something hippie but as a substance that is compatible with motherhood, working out, and enjoying good health.

These evolving trends in cannabis marketing are likely to be followed closely by sector actors such as Flora Growth Corp. (NASDAQ: FLGC) in a bid to stay abreast of the latest trends that can help attain the objectives of the firms.

NOTE TO INVESTORS: The latest news and updates relating to Flora Growth Corp. (NASDAQ: FLGC) are available in the company’s newsroom at https://cnw.fm/FLGC

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — NIDA Seeks Additional Suppliers of Research-Grade Cannabis

The National Institute on Drug Abuse is seeking new partners that can supply cannabis for study purposes. Last week, the federal drug agency posted a notice on its website for organizations authorized by the DEA to grow marijuana that could acquire or produce marijuana and related materials for research.

Before the DEA recently ended the University of Mississippi’s monopoly on cannabis supply and agreed to approve new licenses, the National Institute on Drug Abuse had only a single supplier of marijuana for research. While the agency hasn’t stated how many suppliers it needs, it has listed the criteria for a prospective contract and the responsibilities the new partners would undertake.

In the notice, the agency stated that interested parties would need to be able to procure or produce marijuana, marijuana extract and other marijuana-derived materials for clinical and basic research. In addition, the parties would be required to carry out stability determination, qualitative and quantitative analysis, and recommend suitable conditions for the storage of these products for approved studies.

The agency also revealed that it hoped its studies would focus on less-known cannabinoids such as CBG, CBC and CBN, in addition to better-known ones, including CBD and THC. The agency then noted that organizations that were interested needed to document and demonstrate that they had considerable experience and were capable of administering and coordinating interrelated tasks in a timely and effective manner.

For some time, legislators and experts have been protesting against the exclusive supply of cannabis that the National Institute on Drug Abuse had depended on, arguing that research done using this cannabis had skewed findings. Researchers added that the marijuana’s status under the Controlled Substances Act also hindered studies on marijuana. The status discourages scientists from taking on research on marijuana, as has been stated by Nora Volkow, head of the National Institute on Drug Abuse.

In a recent interview, Volkow revealed that she herself wasn’t keen on going through the taxing process of acquiring approval to conduct research on substances such as cannabis because they were classified under Schedule I. Many hope that once the DEA approves more cannabis manufacturers, the quality and diversity of marijuana products will increase, even if the substance remains classified under Schedule I.

In addition to giving approval to new manufacturers, the Drug Enforcement Administration is planning to increase yearly production quotas for cannabis and psilocybin, among other substances, as demand from the scientific community continues to grow.

As the conditions that companies such as Cannabis Strategic Ventures Inc. (OTC: NUGS) have to meet in order to study marijuana ease, we are likely to see plenty of data-backed information becoming available to the public and policymakers.

NOTE TO INVESTORS: The latest news and updates relating to Cannabis Strategic Ventures Inc. (OTC: NUGS) are available in the company’s newsroom at http://cnw.fm/NUGS

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports on 2022 Annual Meeting Voting

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has released a report on its recent 2022 Annual Meeting and the items that were voted on. The meeting was held on May 31, 2022, at 1 p.m. PT. According to the announcement, 2,927,321 shares of the company were represented in person or by proxy during the meeting; that number comprised 49.2% of Lexaria’s issued share capital as of April 4, 2022, which is the record date of the meeting. All matters voted on during the meeting were passed by a majority. Those matters included electing Chris Bunka, John Docherty, Nicholas Baxter, Ted McKechnie and Albert Reese as directors and appointing Davidson & Company LLP as auditors for the company. In addition, voters approved on an advisory nonbinding basis the compensation paid to executive officers in the 2021 fiscal year and ratified the lawful actions of the directors for the past year.

To view the full press release, visit https://cnw.fm/Oodsu

About Lexaria Bioscience Corp.

Lexaria Bioscience’s patented drug-delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bioabsorption with cannabinoids, antiviral drugs, PDE5 inhibitors and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 25 patents granted and more than 50 patents pending worldwide. For more information about the company, please visit www.LexariaBioscience.com. 

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive SMS text alerts from CannabisNewsWire, text “Cannabis” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

CWCB Expo Arrives in New York To Offer Greater Networking and Business Opportunities In The Cannabis Sector

CWCB Expo is a leading B2B marketplace for networking within the cannabis community. Become a part of the interactive educational sessions, hold unique product displays, participate in panel discussions, and seek the phenomenal opportunities offered by the CWCB platform. The conference is being held on June 2-4, 2022 as an in-person event for the hemp and cannabis business community in New York.

From discovering the more creative products being showcased to making launch announcements, the CWCBExpo is the center place of all cannabis business. Industry thought leaders and eminent personas of the cannabis arena from New York and around the globe will be gracing the event with their presence. They will share their insights and valuable suggestions that will pave the way for the future of the cannabis business.

The event will also host a spectacular assembly of speakers who will discuss all the important aspects of the cannabis spectrum ranging from regulations to the medical and adult use of cannabis.

The line-up of speakers consists of influential personalities namely:

  • Tremaine Wright is the Chairwoman of the New York State Cannabis Control Board and a former member of the New York State Assembly. She looks into the regulatory and tax policies regarding medical and adult-use cannabis in New York State.
  • Gia Morón is the President of Women Grow and the Founder and CEO of GMV Communications. She supervises the company’s operations and strategic partnerships.
  • New York City Mayor Eric Adams appearance on Friday, June 3rd at 1:30 pm

Some important topics at the conference:

  • Trends and opportunities in the cannabis and hemp industries
  • Latest marijuana and hemp investment trends that get the attention of Wall Street
  • Discussion with experts about the infused, edibles and the consumer packaged goods sector
  • Discussions by dispensary owners, retailers, and designers about owning and maintaining a dispensary
  • Licensing & The Illicit Market
  • Challenges of getting into the cannabis and hemp business and being successful

Attendees can meet the experts and leading exhibitors to interact and foster business ties with each other. The workshop and conference program being held at the Expo are knowledge houses to impart essential information and news about the cannabis industry. The thought leadership hosts will be sharing the stage along with some distinguished cannabis experts. They will cover essential   topics like Investing and Industry Progress, Policy and Legislation, Cannabis and Lifestyle, for the three days subsequently.

To learn more, please visit https://cwcbexpo.com/.

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

With a Focus on Accountability, Prime Harvest Inc. Continues to Grow as a Leader in California’s Cannabis Industry

  • Prime Harvest is a California-based tech-driven full-service cannabis corporation focused on direct-to-consumer operations, licensing acquisition, compliance management, and state-wide delivery
  • Prime Harvest fuses integrity into operations, dedicated to redefining the customer experience, being a force for good within the communities they serve, while building a valuable enterprise
  • Member of Community Alliance Program (“CAP”), supports education, arts initiatives, and military veteran organizations in local Southern California
  • Company launched Jaxx Cannabis in 2019, sales increased by 34% in early 2020, hit record 63% gross margin in Q1-2020

From its humble beginnings in 2017 as a cannabis producer in San Diego, Prime Harvest, a technology-driven full-service cannabis corporation, has risen to prominence as a leader in California’s cannabis industry while focusing on enhancing the customer experience, diversity, and giving back to the community. 

Prime Cannabis is horizontally diversified across the entire cannabis value chain with business activities focused on direct-to-consumer operations, licensing acquisition, compliance management, and state-wide delivery. The company continues to expand its footprint throughout California with a proven long-term strategy of investing in the growth and scale of licensed assets while leveraging the power of data-driven technology across its operations.

At the same time, Prime Cannabis focuses on community, the environment, and promoting diversity throughout the organization. Led by a team of reputable experts in their respective fields, the company dedicates activities to setting new operational standards that emphasize sustainability, accountability, and community.

As a proud member of the Community Alliance Program (“CAP”), Prime Harvest supports efforts to improve education, provide resources for military veterans, and promote the arts for children and adults in local communities. As an advocate of cannabis access for medical patients, CAP also leads educational initiatives to help explore the healing attributes of cannabis to treat epilepsy, Post-Traumatic Stress Disorder (“PTSD”), cancer, Chronic Traumatic Encephalopathy (“CTE”), chronic pain, and autism.

Since its early beginnings in 2017 as the “Olive Tree Wellness Center” – a patient association serving the San Diego community – Prime Harvest has provided compliant, first-in-class cannabis products and experiences. Hampered by early legislation limitations that impacted San Diego operations, the company spun its strategy to overcome these challenges and maximize the opportunities that came with operating within the particularly conservative and underserved market. As a result, Prime Harvest rebuilt its operations and launched Jaxx Cannabis – its flagship brand and dispensary.

Jaxx Cannabis enjoyed immediate success, particularly as a result of coronavirus mandates that permitted cannabis dispensaries to remain open. As a result, Jaxx Cannabis drove substantial company growth throughout 2020, providing evidence that the industry is resilient to recessions and economic downturns. Sales increased by 34% at the start of 2020, hitting a record 63% in gross margin by the first quarter (https://cnw.fm/rijiw). 

Prime Harvest is favorably positioned as a leader in California’s cannabis industry, backed by a strong business strategy and anchored by its commitment to community, diversity, and becoming California’s preferred cannabis retailer. The company’s commitment to accountability is fused throughout its operations as it strives to continue growing financially and providing shareholder value.

For more information, visit the company’s website at www.PrimeHarvestInc.com. 

NOTE TO INVESTORS: The latest news and updates relating to Prime Harvest are available in the company’s newsroom at https://cnw.fm/PRIME

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Technology Consistently Enhancing the Oral Administration of Active Pharmaceutical Ingredients

  • A global innovator in drug delivery platforms, Lexaria has developed a patented technology, DehydraTECH(TM) 
  • Through research, Lexaria has evidenced that DehydraTECH enhances the efficiency and speed of orally- administered fat-soluble active pharmaceutical ingredients (“APIs”)
  • Lexaria is consistently enhancing the delivery of APIs that affect current oral formulations: speed of onset, limited absorption, and low membrane permeability
  • Lexaria has conducted numerous ground-breaking studies, some of which open up the possibility of fast-acting oral products that avoid the lung diseases and cancers caused by inhalation of combusted molecules common in smoking

Oral formulations account for approximately 90% of the global share of all pharmaceutical formulations made for human use. Statistics also show that about 60% of all established, commercially available small-molecule drug products today and approximately 84% of all best-selling pharmaceutical products are orally administered. Oral drug administration is preferred because it offers numerous advantages over other delivery methods (for instance, intramuscular, subcutaneous, intravenous, and inhalation), not the least of which is high compliance of patients. Additionally, the drugs can be used to offer localized treatment of affected regions within the gastrointestinal tract.

“Despite these advantages, the development of oral formulations presents several challenges, which are mainly attributed to the physicochemical properties of drugs, including poor water solubility and membrane permeability. In addition, the absorption of drugs can be limited by their poor chemical and biological stability, as well as by physiological barriers, including pH, efflux transporters, and metabolic enzymes,” reads a 2021 review article published in the Frontiers in Pharmacology Journal (https://cnw.fm/lq1sW).

In understanding the shortcomings of orally administered drugs, Lexaria is rising to the occasion, developing a drug delivery technology that solves the aforementioned challenges. Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, has developed DehydraTECH(TM), a patented technology which enhances the efficiency and speed of orally-administered fat-soluble active pharmaceutical ingredients (“API”). 

“DehydraTECH combines lipophilic APIs with specific fatty acid and carrier compounds, thereby improving the way APIs enter the bloodstream while increasing the effectiveness of fat-soluble active molecules allowing lowering overall dosing and promoting healthier oral ingestion methods,” Lexaria explained in its 2021 annual report (https://cnw.fm/7H1hU).

The company began developing DehydraTECH in 2014 and has since strengthened the technology as well as broadened its possible applications. Now, Lexaria’s website notes, the technology “can be applied to many different drugs and other active ingredients such as vitamins in oral formats including tablets, capsules, oral suspensions – and even foods, beverages, and topical preparations.”

Lexaria has also conducted in vitro and in vivo human and/or animal studies that have evidenced the technology’s ability to mask unwanted tastes, improve the speed of onset, increase bioavailability and brain absorption, and lower dosing – thereby reducing drug administration costs – of APIs. 

So far, Lexaria has explored how DehydraTECH improves APIs, not limited to, cannabidiol (“CBD”), oral nicotine, and antiviral drugs, with the company describing its oral nicotine investigations as “ground-breaking studies to open doors previously closed to disruptive new technology, including the possibility of potent and fast-acting ingestible products that avoid the lung diseases and cancers caused by inhalation of combusted molecules common in smoking” (https://cnw.fm/Ld3Vg).

In a series of animal studies staggered between 2018 and 2021, Lexaria evidenced that DehydraTECH delivered considerable nicotine absorption performance improvements compared to controls. The technology resulted in faster delivery of the compound, a higher quantity of peak nicotine delivered to the bloodstream, greater bioavailability, and higher brain absorption (as evidenced by high levels of nicotine in the brain). In its latest animal study, whose results the company released last year, Lexaria revealed that DehydraTECH was between 10x to 20x faster in achieving peak delivery of oral nicotine to the bloodstream than controls. It also attained peak nicotine levels that were up to 10x higher than controls (https://cnw.fm/XpqBK). Now, Lexaria is focusing on the human nicotine study, NIC-H22-1, with dosing expected to begin this summer.

The company hopes that the use of DehydraTECH-nicotine pouches –will help avoid harmful outcomes associated with smoking tobacco, a source of nicotine. Tobacco use causes 480,000 deaths (including passive smokers) annually in the United States (https://cnw.fm/FepeX). Globally, tobacco claims over 8 million lives every year, 7 million of which result from direct tobacco use, while about 1.2 million are caused by the inhalation of secondhand smoke (https://cnw.fm/9aFYx). 

In its quest to promoting healthier alternatives to traditional orally administered drugs as well as morbidity-causing practices such as smoking, Lexaria is simultaneously tapping into multibillion-dollar industries. Valued at an estimated $5.9 billion in 2022, the global nicotine pouches market is projected to grow at a CAGR of 31% to reach $29.6 billion by 2028 (https://cnw.fm/1F5R0). Similarly, the oral drug delivery market, which was valued at $100.05 billion in 2018, is projected to grow at a CAGR of 6.99% to reach $150.06 billion by 2024 (https://cnw.fm/6Pm1a).

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

420 with CNW — VA Declines Certifying a Veteran’s Hemp Because of Marijuana’s Federal Status

Last week, the Department of Veterans Affairs rejected an application made by a veteran  requesting that his hemp product firm be recognized. In its denial letter, the department stated that the department could not endorse the business because it was involved in products derived from the same genus of the marijuana plant, which would give the impression that a federal agency was endorsing the plant.

This rejection highlights the confusion around hemp’s legal status, which is defined as cannabis sativa L., and its derivatives, which contain less than 0.3% THC under U.S. law. Marijuana products with higher THC concentrations are still classified as Schedule I substances and remain illegal under the Controlled Substances Act.

The company in question, Holistic Serendipity LLC, operates under a native ceuticals licensing agreement. The company, which is owned by Zack Zindler, was seeking certification as a veteran-owned, service-disabled small business. This designation would allow the company to compete for contracts in the federal government.

While some federal agencies allow companies to self-certify service-disabled veteran-owned small businesses, the Department of Veterans Affairs requires that businesses be verified through its Center for Verification and Evaluation. Director John Perkins stated in the letter denying the application that verification would grant the company the ability to use the VA’s veteran-owned business trademark, which would give the appearance that the department was promoting the use of a Schedule I controlled substance.

The letter also made it clear that Native Ceuticals Tampa was a hemp company, noting that, based on online research as well as the documentation submitted, it sold products derived from hemp.

Zindler started his company last year in May. His objective, he said, was to offer alternatives to pharmaceuticals and narcotics for members of the military who were recovering from mental health conditions such as post-traumatic stress disorder or physical injuries. In his statement, the Marine veteran revealed that hemp had helped him regulate and process his emotions as well as helped him manage physical ailments, without side effects or dependency.

Zindler also revealed that he’d applied for a federal contracting program in an attempt to reach more military service members, which required him to seek verification from the Department of Veterans’ Affairs as a service-disabled, veteran-owned small business.

Currently, hemp is legal under federal law and was legalized under the 2018 farm bill. Earlier this year, however, a measure was filed in Congress that would increase hemp’s THC limit to 1%.

It is this kind legal or regulatory confusion that indirectly makes it more challenging for entities such as Advanced Container Technologies Inc. (OTC: ACTX) because potential clients may become hesitant after reading stories such as the one Zindler shares.

NOTE TO INVESTORS: The latest news and updates relating to Advanced Container Technologies Inc. (OTC: ACTX) are available in the company’s newsroom at https://cnw.fm/ACTX

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — Appeals Court Says Delta-8 THC Federally Legal

According to a 9th Circuit Court of Appeals panel, products containing delta-8 THC are legal under federal law. The court ruled that the 2018 farm bill was clear and only restricted delta-9 THC to no more than 0.3% of a product on a dry-weight basis. The panel of three judges agreed unanimously that the law doesn’t mention anything about delta-8 THC, so one cannot claim that the substance is illegal under the 2018 farm bill.

Delta-9 THC, commonly called THC, is the most plentiful of all cannabinoids and it is responsible for the “high” that marijuana users experience. This substance is categorized as a controlled substance falling under Schedule 1 of the Controlled Substances Act. However, delta-8 THC occurs in miniscule amounts in a cannabis plant.

That notwithstanding, the latest cultivation as well as cannabis processing methods make it possible for these minor cannabinoids such as delta-8 THC to be extracted in larger amounts and then further processed into finished products. Since delta-8 THC is also psychoactive although to a lesser degree, the cannabinoid has become popular in jurisdictions where marijuana (and subsequently THC) is still prohibited.

The panel of three judges wrote that although delta-8 THC possesses psychoactive properties, the applicable federal law only singles out delta-9 THC while leaving other derivatives to be accepted as legal. The court then stated that it would not substitute its own opinion for the intent of the 2018 farm bill and if any loophole was created, the matter was for Congress to correct that anomaly.

The court ruling resulted from a lawsuit in which AK Futures, a manufacturer of vaping products as well as e-cigarettes, claimed that Boyd Street Bistro had infringed on its copyright and was marketing counterfeits of AK Futures’ products. Those counterfeits contained delta-8 THC. A lower court had issued a preliminary injunction restraining Boyd Street Distro from continuing to sell those products about which a copyright infringement lawsuit had been filed.

Boyd Street Bistro argued that there was no copyright infringement since delta-8 THC was prohibited federally. The appeals court disagreed and upheld the preliminary injunction against Boyd Street Bistro. Boyd Street also told court that it had sourced the delta-8 THC products from an individual who claimed to be a representative of AK Futures, and now that that individual had sold out the batch, there were no plans to procure any more products under that brand.

Counsel representing Boyd Street insisted that there wasn’t any evidence supporting the view that Congressional intent was in favor of legalizing delta-8 THC. If that were the case, numerous state as well as federal agencies would have taken steps to establish regulations preventing its marketing to minors and ensuring consumer safety.

Many of these conflicts over delta-8 THC are being documented across the country, and many advocates are saying that since plenty of research exists about delta-9 THC, it would be better for the entire marijuana industry and companies such as American Cannabis Partners if the federal government ended marijuana prohibition once and for all. This would potentially dampen interest in delta-8 THC, a compound with limited research done about it.

NOTE TO INVESTORS: The latest news and updates relating to American Cannabis Partners are available in the company’s newsroom at https://cnw.fm/ACP

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.